Life sciences major Merck KGaA (MRK: DE) has outlined its strategy for ensuring accelerated growth during a Capital Markets Day on Thursday.
The German company is aiming for group sales of around 25 billion euros ($30 billion) in 2025, where in 2020 this figure was 17.53 billion euros.
Merck expects a major part of this growth to come from the Healthcare division, where medium-term average annual organic sales growth in the mid single-digit percentage range is predicted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze